Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened ...

Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, the firm is refreshing its TTR market ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

The Nasdaq ($NDAQ) reshuffles its Nasdaq-100 index (NDX) annually in December, and the company announced six new additions to ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Strategy, formerly MicroStrategy, retained its place in the Nasdaq 100 during this year’s rebalancing — its first test since joining the benchmark in December ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

The Nasdaq 100 rebalance saw six companies dropped and three new additions, with changes taking effect on December 22, but ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...